Hospitals

Resilinc and Premier Inc. to Launch Healthcare Exchange to Help Hospitals Access Supplies and Ease Shortages During COVID-19

Thursday, April 2, 2020 - 5:44am

The Exchange is a cloud-based platform for the healthcare industry where hospitals interact with vetted peer organizations to identify, locate and exchange critical medical items during the COVID-19 outbreak.

Key Points: 
  • The Exchange is a cloud-based platform for the healthcare industry where hospitals interact with vetted peer organizations to identify, locate and exchange critical medical items during the COVID-19 outbreak.
  • Many hospitals searching for items that are on allocation by suppliers must manually locate other hospitals who have inventory.
  • The Exchange at Resilinc is a modern, cloud-based tool that can expedite communications between hospitals and help them instantly locate and negotiate for medical supplies among thousands of hospitals nationwide.
  • Premier is proud to help found this exchange and cut across traditional boundaries for the benefit of all.

ECS Personnel Aboard USNS Mercy Supporting Navy Efforts to Combat Coronavirus

Wednesday, April 1, 2020 - 9:44pm

On March 17, the USNS Mercy received word that it would deploy to Los Angeles to provide medical care in the Southern California region.

Key Points: 
  • On March 17, the USNS Mercy received word that it would deploy to Los Angeles to provide medical care in the Southern California region.
  • The ECS team worked closely with military and civilian personnel to ready this ship for departure only six days later, on March 23.
  • While the duration of this mission is unknown, ECS is prepared to support the Navy for as long as it takes.
  • The country needs the vital care provided by ships like the USNS Mercy now more than ever, said George Wilson , president of ECS.

Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic

Wednesday, April 1, 2020 - 9:00pm

Merck will support its employees around the world who are uniquely qualified to provide medical services and wish to aid communities affected by the COVID-19 pandemic.

Key Points: 
  • Merck will support its employees around the world who are uniquely qualified to provide medical services and wish to aid communities affected by the COVID-19 pandemic.
  • Pfizer has created a new Global COVID-19 Medical Service Program that empowers medical colleagues to provide diagnostic, treatment, and public health support in the battle against COVID-19.
  • Lilly is deploying its medical professionals to staff a free drive-through COVID-19 testing facility at its corporate headquarters in Indianapolis.
  • Forward-Looking Statement of Eli Lilly and Company, Indianapolis, Ind., USA
    This release contains forward-looking statements regarding Lillys efforts in regard to the novel coronavirus.

Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic

Wednesday, April 1, 2020 - 9:00pm

Merck will support its employees around the world who are uniquely qualified to provide medical services and wish to aid communities affected by the COVID-19 pandemic.

Key Points: 
  • Merck will support its employees around the world who are uniquely qualified to provide medical services and wish to aid communities affected by the COVID-19 pandemic.
  • Pfizer has created a new Global COVID-19 Medical Service Program that empowers medical colleagues to provide diagnostic, treatment, and public health support in the battle against COVID-19.
  • Lilly is deploying its medical professionals to staff a free drive-through COVID-19 testing facility at its corporate headquarters in Indianapolis.
  • Forward-Looking Statement of Eli Lilly and Company, Indianapolis, Ind., USA
    This release contains forward-looking statements regarding Lillys efforts in regard to the novel coronavirus.

Promega GoTaq® Probe 1-Step RT-qPCR System Approved for Use in CDC’s COVID-19 Emergency Use Authorization Diagnostic Panel

Wednesday, April 1, 2020 - 8:55pm

Promega Corporations GoTaq Probe 1-Step RT-qPCR System is now in a Centers for Disease Control and Prevention COVID-19 diagnostic protocol for emergency use.

Key Points: 
  • Promega Corporations GoTaq Probe 1-Step RT-qPCR System is now in a Centers for Disease Control and Prevention COVID-19 diagnostic protocol for emergency use.
  • The Promega tool is an approved master mix option for the CDCs 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel that is available through the CDCs Emergency Use Authorization (EUA).
  • View the full release here: https://www.businesswire.com/news/home/20200401005732/en/
    The Promega GoTaq Probe 1-Step RT-qPCR System is now a recommended master mix option for the Centers for Disease Control and Preventions 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel that is available through the FDAs Emergency Use Authorization.
  • The GoTaq Probe 1-Step RT-qPCR System is a ready-to-use master mix of optimized components for robust RT-qPCR using hydrolysis probes.

SyTrue Offers Free AI-based Solutions to Public Health Organizations to Fight the COVID-19 Pandemic

Wednesday, April 1, 2020 - 8:24pm

In an effort to help researchers and governments battling the COVID-19 pandemic make earlier detection and interventions possible, SyTrue, Inc., a provider of Natural Language Processing (NLP) solutions, today announced the Company will provide its SyHealthTM for Population Health solution free of charge to qualified global public health organizations.

Key Points: 
  • In an effort to help researchers and governments battling the COVID-19 pandemic make earlier detection and interventions possible, SyTrue, Inc., a provider of Natural Language Processing (NLP) solutions, today announced the Company will provide its SyHealthTM for Population Health solution free of charge to qualified global public health organizations.
  • SyTrues suite of solutions can also follow patients over time, creating longitudinal health records.
  • To assist those working tirelessly to battle this pandemic, our SyTrue NLP OSTM platform and solutions can help health systems, global and domestic public health organizations, health plans and researchers tap into this data and make it usable, shareable and actionable in real-time.
  • Accelerated Identification of Patient Cohorts Using SySearch discovery tool, researchers can identify patient cohorts and pandemic trends more quickly.

Premier Inc. Survey: As COVID-19 Spreads to New Hotspots, Hospitals Should Prepare for up to a 17X Surge in Supply Demand

Wednesday, April 1, 2020 - 7:00pm

Premiers survey is the first to quantify surge capacity and supply burn rates, by category, for the provider community, essential facts needed to prepare for an influx of COVID-19 cases.

Key Points: 
  • Premiers survey is the first to quantify surge capacity and supply burn rates, by category, for the provider community, essential facts needed to prepare for an influx of COVID-19 cases.
  • Since our earlier survey of hospitals supply levels, we have much more precise detail on the increased use of supplies, says Premier President Michael J. Alkire.
  • According to the survey, hospitals ranked the supply of N95 respirators as their top concern.
  • Comparing the number of respirators the hospital used before and after confirmed COVID-19 cases were admitted, Premier calculated a surge need of up to 17X.

Cancer Diagnostics Innovator KIYATEC Expands Services to Help Relieve COVID-19 Testing Bottleneck

Wednesday, April 1, 2020 - 5:00pm

By creating additional capacity for RNA extraction, a critical component of the COVID-19 testing process, KIYATEC believes it will help testing laboratories normalize the processing and delivery of test results at a time of unprecedented testing demand and turnaround times.

Key Points: 
  • By creating additional capacity for RNA extraction, a critical component of the COVID-19 testing process, KIYATEC believes it will help testing laboratories normalize the processing and delivery of test results at a time of unprecedented testing demand and turnaround times.
  • Most coronavirus tests rely on RNA extraction as the first technical step; without it, the test cannot be performed.
  • With an already CLIA-certified and operational high complexity lab, KIYATEC is joining the fight against this pandemic by offering its RNA extraction services to COVID-19 testing laboratories.
  • Making RNA extraction services available to COVID-19 testing laboratories is consistent with KIYATECs core goals of improving patient care and outcomes.

Global eHealth Market Expected to Grow with a CAGR of 23% Over the Period, 2019-2024 - ResearchAndMarkets.com

Wednesday, April 1, 2020 - 3:05pm

The global eHealth market is expected to grow with a CAGR of 23% from 2019 to 2024.

Key Points: 
  • The global eHealth market is expected to grow with a CAGR of 23% from 2019 to 2024.
  • Some of the features of Global eHealth Market 2019-2024: Trends, Forecast, and Opportunity Analysis include:
    Market size estimates: Global eHealth market size estimation in terms of value ($M) shipment.
  • Segmentation analysis: Global market size by various applications such as by ehealth type, by service, by end user, and by region
    Regional analysis: Global eHealth market breakdown by North America, Europe, Asia Pacific, and the Rest of the World
    Growth opportunities: Analysis on growth opportunities in different applications and regions for eHealth in the global eHealth market.
  • Strategic analysis: This includes M&A, new product development, and competitive landscape for eHealth in the global eHealth market.

Masimo Announces Preliminary, Unaudited First Quarter 2020 Product Revenue

Wednesday, April 1, 2020 - 2:00pm

Masimo Corporation (Nasdaq: MASI) today announced a preliminary product revenue range for the first quarter ended March 28, 2020, and provided a business update regarding the impact of the Coronavirus (COVID-19) on the Companys full-year 2020 outlook.

Key Points: 
  • Masimo Corporation (Nasdaq: MASI) today announced a preliminary product revenue range for the first quarter ended March 28, 2020, and provided a business update regarding the impact of the Coronavirus (COVID-19) on the Companys full-year 2020 outlook.
  • Masimo expects that its product revenue for the first quarter 2020 will range from $265 million to $271 million, which reflects reported growth of 14.9% to 17.5% over the first quarter of 2019.
  • Management plans to discuss Masimos complete first quarter 2020 financial results after the market closes on Tuesday, April 28, 2020.
  • First Quarter 2020 Financial Results Conference Call on Tuesday, April 28, 2020
    The conference call to review Masimos complete financial results for the first quarter ended March 28, 2020 will begin at 1:30 p.m. PT (4:30 p.m.